Bilawal Ahmed, MD
Hematology & Oncology · Memphis, TNNPI 1164837829
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AstraZeneca at 54.9% of the total. Reporting peaked in 2024 at $3,237 and has fallen 87.0% since, to $421 in 2025. That places this record below the midpoint for hematology & oncology clinicians in TN, where the typical reported total is $5,575.
Across 86 payments — averaging $61.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Pfizer$337
- Genentech USA, Inc.$314
- Exelixis Inc.$298
- Novartis$172
- E.r. Squibb & Sons, L.L.C.$155
- plus $1K from 19 others
Across 11 payments — averaging $3553.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$37K
- Amgen$2K
What the payments were for
- Consulting fees$2,74052%
- Food & beverage$2,45546%
- Education$1052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $2,907 |
| Pfizer | 17 | $337 |
| Genentech USA, Inc. | 4 | $314 |
| Exelixis Inc. | 12 | $298 |
| Novartis | 6 | $172 |
| E.r. Squibb & Sons, L.L.C. | 9 | $155 |
| Bristol Myers Squibb | 2 | $135 |
| Johnson & Johnson(2 entities) | 3 | $131 |
| Rigel Pharmaceuticals, Inc. | 1 | $122 |
| Tempus AI, Inc | 6 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $75 |
| Gilead | 3 | $72 |
| Merck | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $55 |
| Amgen | 2 | $29 |
| AbbVie | 1 | $28 |
| Sanofi | 1 | $26 |
| Integra Lifesciences Corporation | 1 | $21 |
| Dova Pharmaceuticals | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Seagen Inc. | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,300 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 95 | $1,265,757 |
| KeytrudaPembrolizumab | 62 | $689,011 |
| Lupron DepotLeuprolide Acetate | 56 | $615,365 |
| ImfinziDurvalumab | 28 | $340,683 |
| NubeqaDarolutamide | 27 | $326,708 |
| LynparzaOlaparib | 27 | $269,434 |
| Abiraterone Acetate | 96 | $169,432 |
| XgevaDenosumab | 47 | $147,145 |
| ProliaDenosumab | 40 | $64,698 |
| EligardLeuprolide Acetate | 11 | $26,738 |
| Solifenacin Succinate | 21 | $1,962 |
| Oxycodone Hcl | 96 | $1,582 |
| Prednisone | 89 | $584 |
| Bicalutamide | 14 | $508 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckKeytruda | $70 | $689,01162 claims |
| AbbVieLupron Depot | $28 | $615,36556 claims |
| AstraZenecaImfinzi, Lynparza | $2,907 | $610,11655 claims |
| AmgenXgeva, Prolia | $29 | $211,84387 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $15 | $169,43296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Memphis
- Ugochi OguMemphis$250K
- Patricia Adams-GravesMemphis$168K
- Donald GravenorMemphis$166K
- Aleksandar JankovMemphis$163K
- Brion RandolphMemphis$162K
- Kenneth AtagaMemphis$157K
- Raymond OsarogiagbonMemphis$117K
- Saurin ChokshiMemphis$86K
- Clyde JonesMemphis$54K
- Salil GoorhaMemphis$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.